latest news in Biotechnology

Pancreatic Cancer Treatment Shows Promise in Advanced Clinical Trials

Pancreatic Cancer Treatment Shows Promise in Advanced Clinical Trials

London, Saturday, 21 November 2026.
Trial results reveal targeted drug daraxonrasib controlled tumor growth in 90% of patients and eliminated tumors in one in 12, signaling a transformative commercial breakthrough in oncology.

Biotech Firm Cuts Production Costs by Seventy Percent Ahead of Commercial Launch

Biotech Firm Cuts Production Costs by Seventy Percent Ahead of Commercial Launch

New York, Thursday, 19 November 2026.
eXoZymes slashed manufacturing costs for its lead compound below $1,000 per kilogram, securing commercial partner Curia despite posting a $2.24 million third-quarter loss and managing $3.26 million in cash.

Zoar Debuts on the New York Stock Exchange Following Landmark Healthcare Merger

Zoar Debuts on the New York Stock Exchange Following Landmark Healthcare Merger

New York, Wednesday, 18 November 2026.
Impact Biomedical completed its strategic combination with Zoar Limited, debuting on the public market today backed by Zoar Labs’ $77.7 million annual net income and accelerating pipeline commercialization.

Greener Blood Processing: How a New Filter Eliminates Harmful Chemical Waste

Greener Blood Processing: How a New Filter Eliminates Harmful Chemical Waste

Washington, Wednesday, 18 November 2026.
Sangtech Lab has launched the world’s first commercial inline blood filter produced without organic solvents or wastewater, setting a clean-manufacturing standard that slashes environmental compliance costs for medical supply chains.

Promising Leukemia Treatment Results Point to a Clinical Breakthrough

Promising Leukemia Treatment Results Point to a Clinical Breakthrough

Seattle, Monday, 16 November 2026.
Aptevo Therapeutics reported that its lead therapy achieved a 79% remission rate in high-risk leukemia patients, nearly doubling historical benchmarks while the firm advances critical trials.

Direct Gene Editing Inside the Body Nears First US Health Approval

Direct Gene Editing Inside the Body Nears First US Health Approval

Washington, Sunday, 15 November 2026.
The FDA’s pending decision on Intellia’s liver-targeted therapy could mark the first medicine to edit genes directly inside patients, bypassing costly laboratory cell modification to expand patient reach.